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(57) ABSTRACT 
Novel synthases and the corresponding nucleic acids encod 
ing such synthases are disclosed herein. Such synthases 
possess an active site pocket that includes key amino acid 
residues that are modi?ed to generate desired terpenoid 
reaction intermediates and products. Synthase modi?cations 
are designed based on, e.g., the three-dimensional coordi 
nates of tobacco 5-epi-aristolochene synthase, With or With 
out a substrate bound in the active site. 
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SYNTHASES 
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claims bene?t under 35 USC 119(e) of US. Provisional 
Application No. 60/150,262, ?led Aug. 23, 1999, US. 
Provisional Application No. 60/130,628, ?led Apr. 22, 1999, 
and US Provisional Application No. 60/100,993, ?led Sep. 
18, 1998. 
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(GM54029 and GM07240) and NSF (lBW-9408152). 
Therefore, the Unites States Federal Government may have 
certain rights in the invention. 
BACKGROUND OF THE INVENTION 
Isoprenoid compounds are organic molecules produced 
by a Wide range of organisms (e.g., plants, bacteria, fungi, 
etc). To date, over 23,000 individual isoprenoid molecules 
have been characteriZed With tens to hundreds of neW 
structures identi?ed each year. These molecules can ful?ll a 
variety of roles. For eXample, monoterpenes can be used as 
fragrances and ?avors. Sesquiterpenes and diterpenes can 
serve as pheromones, defensive agents, visual pigments, 
antitumor drugs, and components of signal transduction 
pathWays. Triterpenes can serve important functions as 
membrane constituents and precursors of steroid hormones 
and bile acids. Polyprenols function as photoreceptive 
agents and cofactor side chains, and can also eXist as natural 
polymers. 
The diverse molecular compounds produced by the iso 
prenoid pathWay are created from diphosphate esters of 
monounsaturated isoprene units. Isoprenes are added 
together in multiples of 2, 3, or 4 by prenyl transferases to 
make C10, C15, and C20 units, respectively. The C10, C15, 
and C20 molecules, named geranyl diphosphate (GPP), 
farnesyl diphosphate (FPP), and geranylgeranyl diphosphate 
(GGPP), respectively, serve as substrates for terpene syn 
thases. 
Terpene synthases catalyZe the production of isoprenoid 
compounds via one of the most complex reactions knoWn in 
chemistry or biology. In general, terpene synthases are 
moderately siZed enZymes having molecular Weights of 
about 40 to 100 kD. As an enZyme, terpene synthases can be 
classi?ed as having loW to moderate turnover rates coupled 
With exquisite reaction speci?city and preservation of chiral 
ity. Turnover comprises binding of substrate to the enZyme, 
establishment of substrate conformation, conversion of sub 
strate to product and product release. Reactions can be 
performed in vitro in aqueous solvents, typically require 
magnesium ions as cofactors, and the resulting products, 
Which are often highly hydrophobic, can be recovered by 
partitioning into an organic solvent. 
Terpene synthase genes are found in a variety of organ 
isms including bacteria, fungi and plants. SWapping regions 
approximating eXons betWeen different terpene synthases 
has identi?ed functional domains responsible for terminal 
enZymatic steps. For eXample, Work performed on 5-epi 
aristolochene synthase (TEAS) from Nicotiana tabacum 
(tobacco) and Hyoscyamus muticus vetispiradiene synthase 
(HVS) from henbane revealed that eXon 4 and eXon 6, 
respectively, Were responsible for reaction product speci?c 
ity. Combining functional domains resulted in novel 
enZymes capable of synthesiZing neW reaction products 
(US. Pat. No. 5,824,774). 
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Studies have led to proposed reaction mechanisms for 
isoprenoid production; see, e.g., Cane et al., 1985, Bioorg. 
Chem., 13:246—265; Wheeler and Croteau, 1987, Proc. Natl. 
Acad. Sci. USA, 84:4856—4859; and Pyun et al., 1994,Arch. 
Biochem. Biophys., 308:488—496. The studies used sub 
strate analogs and suicide inhibitors (Croteau, 1994, Arch. 
Biochem. Biophys., 251:777—782; Cane et al., 1995, 
Biochemistry, 34:2471—2479; and Croteau et al., 1993, 
Arch. Biochem. Biophys., 307:397—404), as Well as 
chemical-modifying reagents and site-directed mutagenesis 
in efforts to identify amino acids essential for catalysis (Cane 
et al., 1995, Biochemistry, 34:2480—2488; Rajaonarivony et 
al., 1992, Arch. Biochem. Biophys., 296:49—57; and Raja 
onarivony et al., 1992, Arch. Biochem. Biophys., 
299:77—82). HoWever, these studies have resulted in limited 
success in de?ning the active site due to inherent limitations 
With these techniques. 
SUMMARY OF THE INVENTION 
The invention describes a method of identifying alpha 
carbon atoms found in the active site of a terpene synthase 
and describes these atoms in three dimensional space as Well 
as the spatial relationships among them. The present inven 
tion also describes R-groups associated With such alpha 
carbons and methods of altering these R-groups in order to 
create novel terpene synthases capable of generating novel 
reaction products. 
Until the invention taught in this present application, the 
active site of synthase proteins, the amino acid residues 
located therein, the amino acid residues involved in 
catalysis, and the con?guration of ot-carbons and R-groups 
Within the active site have not been knoWn. The current 
invention noW teaches the structure of synthases, as Well as 
provides the means of making and using the information 
obtained therefrom to develop and produce neW and novel 
synthases having neW and novel synthetic capabilities. The 
data generated using the methods described herein are useful 
for creation and production of synthase mutants that can use 
a variety of isoprenoid substrates and produce a variety of 
isoprenoid products. 
In one embodiment, the invention features an isolated 
terpene synthase having about 20% or greater sequence 
identity to residues 265 to 535 of SEQ ID NO: 2. Such a 
synthase comprises nine ot-carbons having interatomic dis 
tances in Angstroms betWeen the ot-carbons that are 12.3 
Angstroms of the interatomic distances shoWn in Table 6. 
The center point of each ot-carbon is positioned Within a 
sphere having a radius of 2.3 Angstroms. The center point of 
each such sphere has the structural coordinates given in 
Table 5. Each ot-carbon has an associated R-group, and the 
synthase has an ordered arrangement of R-groups associated 
With each alpha-carbon other than the ordered arrangements 
of R-groups shoWn in Table 9. The synthase can have about 
25% or greater sequence identity to residues 265 to 535 of 
SEQ ID 2, or about 35% or greater sequence identity to 
residues 265 to 535 of SEQ ID 2. Such a synthase can 
catalyse the formation of a terpenoid product from a monot 
erpene substrate, a sesquiterpene substrate, or a diterpene 
substrate. The product can be a cyclic terpenoid hydrocarbon 
or an acyclic terpenoid hydrocarbon. Either type of product 
can be hydroXylated or non-hydroXylated. The R-group 
associated With ot-carbon 1 can be selected from one of the 
folloWing groups: the group consisting of Cys, Ser, and Thr, 
the group consisting of Phe, Tyr and Trp, the group consist 
ing of Pro, Gly, and Ala, the group consisting of Glu and 
Asp, the group consisting of Met, Ile, Val and Leu, the group 
consisting of Arg and Lys, and the group consisting of Gin, 
US 6,645,762 B2 
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Asn and His. R-groups associated With ot-carbons 2 to 9 can 
be any amino acid except those having the ordered arrange 
ments of Table 9. Similarly, the R-group associated With 
each of ot-carbons 2—9 can be selected independently from 
the group consisting of Cys, Ser and Thr, the group con 
sisting of Phe, Tyr and Trp, the group consisting of Pro, Gly, 
and Ala, the group consisting of Glu and Asp, the group 
consisting of Met, Ile, Val and Leu, the group consisting of 
Arg and Lys, and the group consisting of Gin, Asn and His. 
In these embodiments, R-groups associated With the remain 
ing eight ot-carbons except those having the ordered arrange 
ments of Table 9. 
In some embodiments, the ordered arrangement of 
R-groups associated With ot-carbons 1 to 9 is Trp, Ile, Thr, 
Thr, Tyr, Leu, Cys, Thr and Phe, respectively, Ser, Ile, Thr, 
Thr, Tyr, Leu, Cys, Thr and Tyr, respectively, Trp, Ile, Thr, 
Thr, Tyr, Leu, Trp, Thr and Tyr, respectively, Ser, Ile, Thr, 
Thr, Tyr, Leu, Trp, Thr and Tyr, respectively, or Glu, Ile, Thr, 
Thr, Tyr, Leu, Cys, Thr and Tyr, respectively. 
The invention also features a terpene synthase made by 
aligning the primary amino acid sequence of a preselected 
terpene synthase polypeptide to the amino acid sequence of 
residues 265 to 535 of SEQ ID NO: 2, mutating a nucleic 
acid encoding the preselected polypeptide at one or more 
codons for nine amino acid residues in a region of the 
polypeptide primary amino acid sequence having about 20% 
or greater sequence identity to residues 265 to 535 of SEQ 
ID NO: 2, the nine residues in the polypeptide aligning With 
residues 273, 294, 402, 403, 404, 407, 440, 519 and 520 of 
SEQ ID NO: 2; and expressing the mutated nucleic acid so 
that a mutated terpene synthase is made. 
The invention also features an isolated terpene synthase 
having about 20% or greater sequence identity to residues 
265 to 535 of SEQ ID NO: 2, the synthase comprising 
sixteen ot-carbons having interatomic distances in Ang 
stroms betWeen the ot-carbons that are 12.3 Angstroms of the 
interatomic distances given in Table 4. The center point of 
each ot-carbon is positioned Within a sphere having a radius 
of 2.3 Angstroms. The center point of each of the spheres has 
the structural coordinates given in Table 3. Each ot-carbon 
has an associated R-group, and the synthase has an ordered 
arrangement of R-groups other than the ordered arrange 
ments of R-groups given in Table 8. The synthase can have 
about 25% or greater sequence identity to residues 265 to 
535 of SEQ ID NO: 2, or about 35% or greater sequence 
identity to residues 265 to 535 of SEQ ID NO: 2. The 
synthase can catalyse the formation of a terpenoid product 
from a monoterpene substrate, a sesquiterpene substrate, or 
a diterpene substrate. The product can be, for example, a 
cyclic terpenoid hydrocarbon. The ordered arrangement of 
R-groups in the synthase associated With ot-carbons 1 to 16 
can be Cys, Trp, He, He, Ser, Thr, Thr, Tyr, Leu, Cys, Val, 
Thr, Tyr, Asp, Phe and Thr, respectively. 
The invention also features an isolated terpene synthase 
having about 20% or greater’sequence identity to residues 
265 to 535 of SEQ ID NO: 2, the synthase comprising 
nineteen ot-carbons having interatomic distances in Ang 
stroms betWeen the ot-carbons that are 12.3 Angstroms of the 
interatomic distances given in Table 2. The center point of 
each ot-carbon is positioned Within a sphere having a radius 
of 2.3 Angstroms. The center points of each sphere have the 
structural coordinates given in Table 1. Each ot-carbon has 
an associated R-group, and the synthase has an ordered 
arrangement of the R-groups other than the ordered arrange 
ments of R-groups given in Table 7. The synthase can have 
about 25% or greater sequence identity to residues 265 to 
535 of SEQ ID NO: 2, or about 35% or greater sequence 
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identity to residues 265 to 535 of SEQ ID NO: 2. The 
synthase can catalyse the formation of a terpenoid product 
from a monoterpene substrate, a sesquiterpene substrate, or 
a diterpene substrate. The product can be, for example, a 
cyclic terpenoid hydrocarbon. 
The invention also features an isolated protein comprising 
a ?rst domain having an amino terminal end and a carboxyl 
terminal end. The ?rst domain comprises amino acids that 
align structurally In three-dimensional space With a glycosyl 
hydrolase catalytic core, the glycosyl hydrolase catalytic 
core selected from the group consisting of amino acids 36 to 
230 of glucoamylase protein databank (PDB) code 3GLY of 
Aspergillus awamori and amino acids 36 to 230 of endo 
glucanase CelD PDB code 1CLC. The isolated protein also 
comprises a second domain having an amino terminal end 
and carboxyl terminal end. The second domain comprises 
amino acids that align structurally in three-dimensional 
space With avian FPP synthase. The carboxyl terminal end of 
the ?rst domain is linked to the amino terminal end of the 
second domain. The second domain has about 20% or 
greater sequence identity to residues 265 to 535 of SEQ ID 
NO: 2, and comprises nine ot-carbons having interatomic 
distances in Angstroms betWeen the ot-carbons that are 12.3 
Angstroms of the interatomic distances given in Table 6. The 
center point of each ot-carbon is positioned Within a sphere 
having a radius of 2.3 Angstroms, the center point of each 
sphere having the structural coordinates given in Table 5. 
Each ot-carbon has an associated R-group, and the synthase 
has an ordered arrangement of R-groups other than the 
ordered arrangements of R-groups given in Table 9. The 
protein can have about 25% or greater sequence identity to 
SEQ ID NO: 2, or about 35% or greater sequence identity to 
SEQ ID NO: 2. The synthase can catalyse the formation of 
a terpenoid product from a monoterpene substrate, a ses 
quiterpene substrate, or a diterpene substrate. The product 
can be, for example, a cyclic terpenoid hydrocarbon. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 343 to 606 of SEQ ID NO: 20, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 348, 351, 372, 375, 376, 454, 479, 
480, 481, 482, 485, 519, 523, 597, 600, 601, 605, 607 and 
608 of SEQ ID NO: 20 are residues other than amino acids 
Y,L, C, I,T,Y,S, C, G,H,S,L, G,F, G,Y,D,YandS, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 316 to 586 of SEQ ID NO: 22, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 321, 324, 345, 348, 349, 427, 452, 
453, 454, 455, 458, 492, 496, 569, 572, 573, 577, 579 and 
580 of SEQ ID NO: 22 are residues other than amino acids 
C,W, N, I, T,Y, S, I, S, G, M, L, D,A, M,Y, D, H and G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more ordered arrange 
ments of residues as given in Table 7 are not found in such 
a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 352 to 622 of SEQ ID NO: 58, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 357, 360, 381, 384, 385, 463, 487, 
US 6,645,762 B2 
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488, 489, 490, 493, 528, 532, 606, 609, 610, 614, 616 and 
617 of SEQ ID NO: 58 are residues other than amino acids 
Y,M, C,V,T, F,V,S, S, G,I,L, G, F,V,Y,D,YandT, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to amino 
acid residues 272 to 540 encoded by SEQ ID NO: 33, 
Wherein one or more amino acid residues of the synthase that 
align With amino acid residues at positions 277, 280, 301, 
304, 305, 383, 408, 409, 410, 411, 414, 448, 452, 524, 527, 
528, 532, 534 and 535 encoded by SEQ ID NOS: 33 are 
residues other than amino acids G, W, I, A, S, Y, T, S, G, Y, 
L, C, D, M, L, Y, D, Y and T, respectively. In some 
embodiments, the sequence identity can be about 20% or 
greater, 25% or greater, or 35% or greater. In some 
embodiments, one or more of the ordered arrangements of 
residues as given in Table 7 are not found in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or-greater sequence identity to resi 
dues 319 to 571 of SEQ ID NO: 42, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 324, 327, 348, 351, 352, 430, 455, 
456, 457, 458, 461, 495, 499, 571, 574, 575, 579, 581 and 
582 of SEQ ID NO: 42 are residues other than amino acids 
I,W,V,I, S,Y,T,T, G, L,V,I,N,T, S,Y,D,Y,andT, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 579 to 847 of SEQ ID NO: 44, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 584, 587, 606, 609, 610, 688, 713, 
714, 715, 716, 719, 753, 757, 831, 834, 835, 839, 841 and 
842 of SEQ ID NO: 44 are residues other than amino acids 
V,S, G, Q,V,Y,S,V,G,L, C,W, N,V,F,Y,D,Yand G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 495 to 767 of SEQ ID NO: 46, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 500, 503, 524, 527, 528, 606, 631, 
632, 633, 634, 637, 674, 678, 751, 754, 755, 759, 761 and 
762 of SEQ ID NO: 46 are residues other than amino acids 
F, L, A, Q, T, Y, S, I, G, Q, L, S, D, T, I, F, D, F and G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 295 to 564 of SEQ ID NO: 48, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 300, 303, 324, 327, 328, 406, 431, 
432, 433, 434, 437, 471, 475, 548, 551, 552, 556, 558 and 
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559 of SEQ ID NO: 48 are residues other than amino acids 
Y,W,A, C, T,Y, S, S, G, M, L, G, D, L, I,Y, D,LandY, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 307 to 578 of SEQ ID NO: 50, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 312, 315, 336,339, 340,419, 444, 
445, 446, 447, 450, 484, 488,562, 565, 566, 570, 572 and 
573 of SEQ ID NO: 50 are residues other than amino acids 
F,W,A, M, T,Y, N, T, G, M, L, S, D, I, M,Y, D,F and S, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 264 to 533 of SEQ ID NO: 52, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 269, 272, 293, 296, 297, 375, 
401,402, 403, 404, 407, 441, 445, 517, 520, 521, 525, 527 
and 528 of SEQ ID NO: 52 are residues other than amino 
acids C, W, L, T, S, Y, S, A, G, Y, I, A, N, A, L, Y, D, Y and 
S, respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 585 to 853 of SEQ ID NO: 56, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 590, 593, 614, 617, 618, 696, 721, 
722, 723, 724, 727, 761, 765, 837, 840, 841, 845, 847 and 
848 of SEQ ID NO: 56 are residues other than amino acids 
I, S, S,T,V,Y,S,I,A,L,V, G,N,M,F,Y,D,LandT, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 307 to 574 of SEQ ID NO: 54, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 312, 315, 336, 339, 340, 418,443, 
444, 445, 446, 449, 483, 487, 560, 563, 564, 566, 568 and 
569 of SEQ ID NO: 54 are residues other than amino acids 
C, W, I, I, T, Y, S, I, S, A, l, L, D, A, I, Y, D, D and G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 309 to 577 of SEQ ID NO: 24, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 314, 317, 338, 341, 342, 420, 446, 
447, 448, 449, 452, 485, 489, 560, 563, 564, 569, 571 and 
572 of SEQ ID NO: 24 are residues other than amino acids 
US 6,645,762 B2 
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C,W,N,V,T,Y,I, G, G,I,L,L,D,A,I,Y,D,Fand G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 315 to 584 of SEQ ID NO: 26, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 320, 323, 344, 347, 348, 426, 451, 
452, 453, 454, 457, 492, 496, 568, 571, 572, 576, 578 and 
579 of SEQ ID NO: 26 are residues other than amino acids 
S,W, I,A,T,Y,S,V,A, S, I,L, D,A, I,Y,D, F, and G, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 265 to 536 of SEQ ID NO: 28, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 270, 273, 294, 297, 298, 376, 401, 
402, 403, 404, 407, 440, 444, 518, 521, 522, 528, 530 and 
531 of SEQ ID NO: 28 are residues other than amino acids 
A,W,V,C,G,F,T,S,C,I,M,G,N,C,S,ZD,YandS, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 342 to 612 of SEQ ID NO: 30, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 347, 350, 371, 374, 375, 453, 478, 
479, 480, 481, 483, 518, 522, 596, 599, 600, 604, 606 and 
607 of SEQ ID NO: 30 are residues other than amino acids 
F, L, C,V,T,Y,S,S,A,Y,V,L, G, L,L,Y,D,F andS, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more of the ordered 
arrangements of residues as given in Table 7 are not found 
in such a synthase. 
The invention also features an isolated synthase having a 
region With about 40% or greater sequence identity to 
residues 273 to 541 of SEQ ID NO: 32, Wherein one or more 
amino acid residues of the synthase that align With amino 
acid residues at positions 278, 281, 302, 305, 306, 384, 409, 
410, 411, 412, 415, 448, 452, 524, 527, 528, 533, 535 and 
536 of SEQ ID NO: 32 are residues other than amino acids 
C,W, I, I,S,Y,T, S,T,Y,L, C, D,I,T,Y,D,YandT, 
respectively. In some embodiments, the sequence identity 
can be about 20% or greater, 25% or greater, or 35% or 
greater. In some embodiments, one or more ordered arrange 
ments of residues as given in Table 7 are not found in such 
a synthase. 
The invention also features a method for making a terpene 
synthase, comprising identifying, in a preselected polypep 
tide having a region With 20% or greater sequence identity 
to residues 265 to 535 of SEQ ID NO: 2, nine amino acid 
residues Whose ot-carbons have interatomic distances in 
Angstroms betWeen the ot-carbons that are 12.3 Angstroms 
of the interatomic distances given in Table 6. The center 
point of each ot-carbon is positioned Within a sphere having 
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a radius of 2.3 Angstroms. The center point of each sphere 
has the structural coordinates given in Table 5. The method 
then comprises synthesiZing a polypeptide that is modi?ed 
from the preselected polypeptide. The modi?ed polypeptide 
has one or more R-groups associated With the nine 
ot-carbons other than the R-groups associated With the 
ot-carbons in the preselected polypeptide. The synthesiZing 
step can comprise the formation of a nucleic acid encoding 
the preselected polypeptide in Which the coding sequence 
for one or more amino acids corresponding to the nine 
ot-carbons is replaced by a coding sequence that codes for an 
amino acid different from the amino acid present in the 
preselected polypeptide. The preselected polypeptide can be, 
for example, any one of the polypeptides given in SEQ ID 
NOS: 2, 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42, 
44, 46, 48, 50, 52, 54, 56, or 58. 
The invention also features a method of using a terpene 
synthase, comprising identifying, in a preselected polypep 
tide having a region With 20% or greater sequence identity 
to residues 265 to 535 of SEQ ID NO: 2, amino acid residues 
at nine positions that align With amino acid residues 273, 
294, 402, 403, 404, 407, 440, 519 and 520 of SEQ ID NO: 
2; and synthesiZing a polypeptide that is modi?ed from the 
preselected polypeptide. The novel polypeptide is modi?ed 
by having amino acid residues at one or more of the nine 
positions other than the amino acid residues present in the 
preselected polypeptide. In some embodiments, the identi 
fying step can comprise identifying siXteen amino acid 
residues in the preselected polypeptide that align With amino 
acid residues 270, 273, 294, 297, 298, 402, 403, 404, 407, 
440, 516, 519, 520, 525, 527 and 528 of SEQ ID NO: 2, and 
the synthesiZing step can comprise synthesiZing a polypep 
tide that is modi?ed from the preselected polypeptide, the 
modi?ed polypeptide having amino acid residues at one or 
more of the siXteen positions other than the amino acid 
residues present in the preselected polypeptide. In some 
embodiments, the identifying step can comprise identifying 
nineteen amino acid residues in the preselected polypeptide 
that align With amino acid residues 270, 273, 294, 297, 298, 
376, 401, 402, 403, 404, 407, 440, 444, 516, 519, 520, 525, 
527 and 528 of SEQ ID NO: 2, and the synthesiZing step can 
comprise synthesiZing a polypeptide that is modi?ed from 
the preselected polypeptide, the modi?ed polypeptide hav 
ing amino acid residues at one or more of the nineteen 
positions other than the amino acid residues present in the 
preselected polypeptide. The synthesiZing step can comprise 
the formation of a nucleic acid encoding the preselected 
polypeptide in Which the coding sequence in the nucleic acid 
coding for one or more of the identi?ed amino acid residues 
is replaced by a coding sequence that encodes an amino acid 
different from the amino acid present in the preselected 
polypeptide. The preselected polypeptide can be, for 
eXample, any one of the polypeptides given in SEQ ID NOS: 
2, 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42, 44, 
46, 48, 50, 52, 54, 56, or 58. The method can further 
comprise: contacting the modi?ed polypeptide With an iso 
prenoid substrate under conditions effective for the com 
pound to bind the polypeptide; and measuring the ability of 
the modi?ed polypeptide to catalyZe the formation of a 
reaction product from the isoprenoid substrate. The iso 
prenoid substrate can be a monoterpene, a sesquiterpene, or 
a diterpene. 
The invention also features a method of making a terpene 
synthase, comprising creating a population of nucleic acid 
molecules that encode polypeptides, the population having 
members that differ from one another at one or more of nine 
codons specifying amino acids of a preselected terpene 
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synthase having a region With about 20% or greater 
sequence identity to residues 265 to 535 of SEQ ID NO: 2, 
ot-carbons of the nine amino acids having interatomic dis 
tances in Angstroms betWeen the ot-carbons that are 12.3 
Angstroms of the interatomic distances given in Table 6. The 
center point of each ot-carbon is positioned Within a sphere 
having a radius of 2.3 Angstroms, and the center point of 
each sphere has the structural coordinates given in Table 5. 
In some embodiments, the codons specify amino acids as 
described in Tables 1—2 or 3—4 of a preselected terpene 
synthase. A portion, or all, of the nucleic acid population is 
expressed so that a population of polypeptides is made. At 
least one member of the population of polypeptides is a 
mutant terpene synthase. The expressing step can comprise 
in vitro transcription and in vitro translation of the nucleic 
acid population. In some embodiments, the expressing step 
comprises cloning members of the nucleic acid population 
into an expression vector, introducing the expression vector 
into host cells and expressing the cloned nucleic acid 
population members in the host cells so that the population 
of polypeptides is made. The preselected terpene synthase 
polypeptide can be a monoterpene synthase, a sesquiterpene 
synthase, or a diterpene synthase. The host cells can be 
prokaryotic cells or eukaryotic cells, including, Without 
limitation, bacterial cells, fungal cells, and animal cells, e.g., 
mammalian cells or insect cells. The host cells can also be 
plant cells, e.g., a cell from a Graminaceae plant, a cell from 
a Legumineae plant, a cell from a Solanaceae plant, a cell 
from a Brassicaeae plant or a cell from a Conifereae plant. 
The invention also features a nucleic acid encoding a 
synthase as described herein, and a host cell containing such 
a nucleic acid. The invention also features a transgenic plant 
containing such a nucleic acid, or a transgenic animal cell 
culture containing such a nucleic acid. 
In some embodiments, a synthase polypeptide of the 
invention comprises a domain that contains an active site 
comprised of nine ot-carbon atoms having the coordinates of 
Table 5, and interatomic distances betWeen the ot-carbons 
12.3 angstroms of the distances given in Table 6. The 
ot-carbon atoms align structurally in three dimensional space 
in the presence or absence of bound substrate or substrate 
analogue, With avian FPP synthase. In another embodiment, 
a synthase of this invention comprises the folloWing: a 
?rst domain containing amino acid residues that align in 
three-dimensional space (in solution or crystal form, and 
either having a bound or unbound substrate) With a glycosyl 
hydrolase catalytic core selected from the group consisting 
of (a) amino acids 36—230 of glycosyl hydrolase (PDB code 
3GLY) of Aspergillus awarmori, and (b) amino acids 
36—230 of endogluconase CellB (PDB code 1CLC), and (ii) 
a second domain that aligns structurally in three dimensional 
space With or Without substrate or substrate analogues bound 
in the active site With avian FPP synthase. The second 
domain contains an active site comprised of nine, sixteen or 
nineteen ot-carbon atoms having the structural coordinates 
and interatomic distances of Tables 1—2, 3—4 or 5—6. These 
ot-carbon atoms have R-groups attached thereto that can 
interact, either directly or indirectly, With an isoprenoid 
substrate. 
The invention also features a method for generating 
mutant terpene synthases possessing catalytic activity. The 
method comprises the steps of (a) providing a crystallo 
graphic model of a preselected catalytically active terpene 
synthase having an active site, and (b) using the model to 
design a terpene synthase having at least one altered 
R-group in the active site relative to the preselected syn 
thase. The invention also features terpene synthases having 
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altered substrate speci?city, methods of making the same, 
and procedures for generating three-dimensional structures 
thereof. 
Although methods and materials similar or equivalent to 
those described herein can be used to practice the invention, 
suitable methods and materials are described beloW. All 
publications, patent applications, patents and other refer 
ences mentioned herein are incorporated by reference in 
their entirety. 
Other aspects, embodiments, advantages, and features of 
the present invention Will become apparent from the speci 
?cation. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1. Schematic representation of tobacco 5-epi 
aristolochene synthase (TEAS) With bound famesyl 
hydroxyphosphonate (FHP), prepared using the RIBBONS 
softWare program of Carson, M. and Bugg, C., J. Mol. 
Graphics 4:121 (1986). Cylinders 1—8 and A represent 
ot-helices in the NH2-terminal domain; cylinders C, D, D1, 
D2, B, F, G1, G2, H1, H2, H3, I and ot-l represent ot-helices 
in the COOH-terminal domain. 
FIG. 2. Structure of tWenty natural amino acids shoWing 
ot-carbons and associated R-groups. 
FIG. 3. Autoradiogram of an argentation thin-layer chro 
matogram of terpenoid hydrocarbon products made by 
TEAS and mutant TEAS enZymes using GGPP as a sub 
strate. DM: W273S/C440W mutant TEAS enZyme. 
FIG. 4. Autoradiogram of an argentation thin-layer chro 
matogram of terpenoid hydrocarbon products made by 
TEAS and mutant TEAS enZymes using FPP as a substrate. 
BRIEF DESCRIPTION OF TABLES 
Table 1. X-ray crystallographic structural coordinates for 
19 ot-carbons found in the active site of a terpene synthase. 
Table 2. Interatomic distances in Angstroms betWeen each 
ot-carbon of Table 1. Each ot-carbon occupies a sphere 
having a radius of 2.3 Angstroms. Interatomic distances are 
calculated from the center point of each sphere. 
Table 3. X-ray crystallographic structural coordinates for 
16 ot-carbons found in the active site of a terpene synthase. 
Table 4. Interatomic distances in Angstroms betWeen each 
ot-carbon of Table 3. Each ot-carbon occupies a sphere 
having a radius of 2.3 Angstroms. Interatomic distances are 
calculated from the center point of each sphere. 
Table 5. X-ray crystallographic structural coordinates for 
nine ot-carbons found in the active site of a terpene synthase. 
Table 6. Interatomic distances in Angstroms betWeen each 
ot-carbon of Table 5. Each ot-carbon occupies a sphere 
having a radius of 2.3 Angstroms. Interatomic distances are 
calculated from the center point of each sphere. 
Table 7. Ordered arrangement of R-groups not found 
associated With the ot-carbons of Table 1. 
Table 8. Ordered arrangement of R-groups not found 
associated With the ot-carbons of Table 3. 
Table 9. Ordered arrangement of R-groups not found 
associated With the ot-carbons of Table 5. 
Table 10. X-ray structural coordinates for TEAS having 
the substrate analog FHP bound in the active site. 
Table 11. X-ray structural coordinates for TEAS in the 
absence of substrate. 
Table 12. Alignment of residues 265—535 of TEAS With 
a limonene synthase, SEQ ID NO: 22, using the BLASTp 
alignment program. 
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Table 13. Alignment of residues 579 to 847 of SEQ ID 
NO:44 With SEQ ID NO:26, using the BLASTp program. 
Table 14. Alignment of residues 265 to 535 of TEAS With 
SEQ ID NO:48, using the BLASTp program. 
Table 15. Alignment of residues 307 to 593 of SEQ ID 
NO:50 With SEQ ID NO:56 using the BLASTp prograrn. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO:1 is the DNA coding sequence for a tobacco 
5-epi-aristolochene synthase (TEAS) protein. Genbank No: 
Q40577. 
SEQ ID NO:2 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:1. 
SEQ ID NO:3 is the DNA coding sequence for a TEAS 
protein in Which the codon for Trp273 has been changed to 
a codon for Glu. 
SEQ ID NO:4 is the amino acid sequence for the W273E 
protein encoded by the TEAS DNA of SEQ ID NO:3. 
SEQ ID NO:5 is the DNA coding sequence for a TEAS 
protein in Which the codon for Tyr520 has been changed to 
a codon for Phe. 
SEQ ID NO:6 is the amino acid sequence for the Y520F 
protein encoded by the TEAS DNA of SEQ ID NO:5. 
SEQ ID NO:7 is the DNA coding sequence for a TEAS 
protein in Which the codon for Tyr527 has been changed to 
a codon for Phe. 
SEQ ID NO:8 is the amino acid sequence for the Y527F 
protein encoded by the TEAS DNA of SEQ ID NO:7. 
SEQ ID NO:9 is the DNA coding sequence for a TEAS 
protein in Which the codon for Trp273 has been changed to 
a codon for Ser and the codon for Cys440 has been changed 
to a codon for Trp. 
SEQ ID NO:10 is the amino acid sequence for the 
W273S/C440W protein encoded by the TEAS DNA of SEQ 
ID N019. 
SEQ ID NO:11 is the DNA coding sequence for TEAS 
proteins in Which the codons for Tyr406 and Leu407 have 
each been changed to the nucleotides NNS. 
SEQ ID NO:12 is the amino acid sequence for the 
population of Y406X/L407X proteins encoded by the TEAS 
DNA of SEQ ID NO:11, Where X is any naturally occurring 
amino acid. 
SEQ ID NO:13 is a DNA prirner sequence. 
SEQ ID NO:14 is a DNA prirner sequence. 
SEQ ID NO:15 is a DNA prirner sequence. 
SEQ ID NO:16 is a DNA prirner sequence. 
SEQ ID NO:17 is a DNA prirner sequence. 
SEQ ID NO:18 is a DNA prirner sequence. 
SEQ ID NO:19 is the DNA coding sequence for a grand 
?r pinene synthase. Genbank Accession No: U87909. 
SEQ ID NO:20 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:19. 
SEQ ID NO:21 is the DNA coding sequence for a 
spearrnint lirnonene synthase. Genbank Accession No: 
L13459. 
SEQ ID NO:22 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:21. 
SEQ ID NO:23 is the DNA coding sequence for a sage 1, 
8 cineole synthase. Genbank Accession No: AF051899. 
SEQ ID NO:24 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:23. 
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SEQ ID NO:25 is the DNA coding sequence for a sage 
bornyl diphosphate synthase. Genbank Accession No: 
AF051900. 
SEQ ID NO:26 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:25. 
SEQ ID NO:27 is the DNA coding sequence for a mint 
E-b-farnesene synthase. Genbank Accession No: AF 024615. 
SEQ ID NO:28 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:27. 
SEQ ID NO:29 is the DNA coding sequence for a grand 
?r rnyrcene synthase. Genbank Accession No: U87908. 
SEQ ID NO130 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:29. 
SEQ ID NO:31 is the DNA coding sequence for a potato 
vetaspiradiene synthase. Genbank Accession No: 
AB022598. 
SEQ ID NO132 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:31. 
SEQ ID NO133 is the genomic DNA coding sequence for 
a cotton delta-cadinene synthase. Genbank Accession No: 
Y18484. 
SEQ ID NOS:34—40 are the amino acid sequences for the 
eXons encoded by the DNA of SEQ ID NO:33. 
SEQ ID NO:41 is the DNA coding sequence for a castor 
bean casbene synthase. Genbank Accession No: L32134. 
SEQ ID NO:42 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:41. 
SEQ ID NO:43 is the DNA coding sequence for a yeW 
taXadiene synthase. Genbank Accession No: U48796. 
SEQ ID NO:44 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:43. 
SEQ ID NO:45 is the DNA coding sequence for a grand 
?r E-alpha-bisabolene synthase. Genbank Accession No: 
AF006194. 
SEQ ID NO:46 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:45. 
SEQ ID NO:47 is the DNA coding sequence for a grand 
?r delta-selinene synthase. Genbank Accession No: U92266. 
SEQ ID NO:48 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:47. 
SEQ ID NO:49 is the DNA coding sequence for a grand 
?r garnrna-hurnulene synthase. Genbank Accession No: 
U92267. 
SEQ ID NO:50 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:49. 
SEQ ID NO:51 is the DNA coding sequence for a tomato 
gerrnacrene C synthase. Genbank Accession No: AF 035 631. 
SEQ ID NO:52 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:51. 
SEQ ID NO:53 is the DNA coding sequence for a 
sage+sabinene synthase. Genbank Accession No: 
AF051901. 
SEQ ID NO:54 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:53. 
SEQ ID NO:55 is the DNA coding sequence for a grand 
?r abietadiene synthase. Genbank Accession No: U50768. 
SEQ ID NO:56 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:55. 
SEQ ID NO:57 is the DNA coding sequence for a grand 
?r lirnonene synthase. Genbank Accession No. AF006193. 
SEQ ID NO:58 is the amino acid sequence for the protein 
encoded by the DNA of SEQ ID NO:57. 
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DETAILED DESCRIPTION 
The following terms are used herein: 
“(x-carbon” refers to the chiral carbon atom found in an 
amino acid residue. Four substituents are covalently bound 
to the ot-carbon, including an amino group, a carboxyl 
group, a hydrogen atom, and an R-group. 
“R-group” refers to a substituent attached to the ot-carbon 
of an amino acid residue that is not involved in peptide bond 
formation in a protein. An R-group is an important deter 
minant of the overall chemical character of an amino acid. 
The tWenty naturally occurring amino acids found in pro 
teins and the R-groups associated With the ot-carbon of each 
amino acid are listed in FIG. 2. The three-letter and one 
letter abbreviations for naturally occurring amino acids are 
sometimes used herein to refer to the R-group associated 
With a particular amino acid. 
“Naturally occurring amino acid” includes L-isomers of 
the tWenty amino acids naturally occurring in proteins. 
Naturally occurring amino acids are glycine, alanine, valine, 
leucine, isoleucine, serine, methionine, threonine, 
phenylalanine, tyrosine, tryptophan, cysteine, proline, 
histidine, aspartic acid, asparagine, glutamic acid, 
glutamine, arginine, and lysine. Unless specially indicated, 
all amino acids referred to in this application are in the 
L-form. Three-letter and one-letter abbreviations are some 
times used herein to refer to naturally occurring amino acids. 
These abbreviations are knoWn in the art. 
“Unnatural amino acid” includes amino acids that are not 
naturally found in proteins. Examples of unnatural amino 
acids included herein are racemic mixtures of selenocysteine 
and selenomethionine. In addition, unnatural amino acids 
include the D or L forms of norleucine, para 
nitrophenylalanine, homophenylalanine, para 
?uorophenylalanine, 3-amino-2-benZylpropionic acid, 
homoarginine, D-phenylalanine, and the like. 
“Positively charged amino acid” includes any naturally 
occurring or unnatural amino acid having an R-group that 
carries a positive charge under normal physiological condi 
tions. Examples of positively charged, naturally occurring 
amino acids include arginine and lysine. 
“Negatively charged amino acid” includes any naturally 
occurring or unnatural amino acid having an R-group that 
carries a negative charge under normal physiological con 
ditions. Examples of negatively charged, naturally occurring 
amino acids include aspartic acid and glutamic acid. 
“Hydrophobic amino acid” includes any naturally occur 
ring or unnatural amino acid having an uncharged, nonpolar 
side chain under normal physiological conditions. Examples 
of naturally occurring hydrophobic amino acids are leucine, 
isoleucine, valine and methionine. 
“Hydrophilic amino acid” includes any naturally occur 
ring or unnatural amino acid having a charged polar side 
chain. Examples of naturally occurring hydrophilic amino 
acids include serine, threonine and cysteine. 
“Mutant terpene synthase” or “mutated terpene synthase” 
refers to a synthase polypeptide having a primary amino acid 
sequence. The center point of the ot-carbon of nine residues 
of the polypeptide is positioned Within a sphere having a 
radius of 2.3 Angstroms; the center points of the nine 
spheres have the structural coordinates of Table 5 or coor 
dinates Which can be rotated and/or translated to coincide 
With the coordinates of Table 5. The relative interatomic 
distances betWeen the nine ot-carbons is 12.3 angstroms of 
the interatomic distances given in Table 6. Each ot-carbon 
has an associated R-group. Amutant synthase differs from a 
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non-mutant synthase in the ordered arrangement of 
R-groups associated With the nine ot-carbons. A mutant 
synthase has an ordered arrangement of R-groups on the 
nine ot-carbons other than the ordered arrangements of 
R-groups listed in Table 9. R-groups associated With other 
ot-carbons of the synthase primary amino acid sequence may 
or may not be the same as in a non-mutated synthase. 
In some embodiments, a mutant synthase refers to a 
synthase in Which the center point of the ot-carbon of sixteen 
residues of the polypeptide is positioned Within a sphere 
having a radius of 2.3 Angstroms; the center points of the 
sixteen spheres have the structural coordinates of Table 3 or 
coordinates Which can be rotated and/or translated to coin 
cide With the coordinates of Table 3. The relative interatomic 
distances betWeen the nine ot-carbons is 12.3 angstroms of 
the interatomic distances given in Table 4. Each ot-carbon 
has an associated R-group. Amutant synthase differs from a 
non-mutant synthase in the ordered arrangement of 
R-groups associated With the sixteen ot-carbons. A mutant 
synthase has an ordered arrangement of R-groups on the 
sixteen ot-carbons other than the ordered arrangements of 
R-groups listed in Table 8. R-groups associated With other 
ot-carbons of the synthase primary amino acid sequence may 
or may not be the same as in a non-mutated synthase. 
In some embodiments, a mutant synthase refers to a 
synthase in Which the center point of the ot-carbon of 
nineteen residues of the polypeptide is positioned Within a 
sphere having a radius of 2.3 Angstroms; the center points 
of the nineteen spheres have the three dimensional coordi 
nates of Table 1 or coordinates Which can be rotated and/or 
translated to coincide With the coordinates of Table 1. The 
relative interatomic distances betWeen the nineteen 
ot-carbons is 12.3 angstroms of the interatomic distances 
given in Table 2. Each ot-carbon has an associated R-group. 
A mutant synthase differs from a non-mutant synthase in the 
ordered arrangement of R-groups associated With the nine 
teen ot-carbons. A mutant synthase has an ordered arrange 
ment of R-groups on the nineteen ot-carbons other than the 
ordered arrangements of R-groups listed in Table 7. 
R-groups associated With other ot-carbons of the synthase 
primary amino acid sequence may or may not be the same 
as in a non-mutated synthase. 
“Nonmutated synthase” or “non-mutant synthase” 
includes a synthase having a primary amino acid sequence 
comprising nine, sixteen, or nineteen amino acid residues. 
The center point of each ot-carbon of these residues is 
positioned Within a sphere having a radius of 2.3 Angstroms; 
the center points of the spheres have the three dimensional 
coordinates of Tables 5, 3, or 1, respectively, or coordinates 
Which can be rotated and/or translated to coincide With the 
coordinates of Tables 5, 3, or 1. The relative interatomic 
distances betWeen the nine, sixteen, or nineteen ot-carbons is 
12.3 angstroms of the interatomic distances given in Tables 
6, 4, or 2, respectively. Each ot-carbon has an associated 
R-group. Anon-mutant synthase has an ordered arrangement 
of R-groups on the nine, sixteen, or nineteen ot-carbons as 
listed in Tables 9, 8, or 7, respectively. 
“Degenerate variations thereof” refers to variants of a 
gene coding sequence by Which the same polypeptide is 
encoded by different nucleotide sequences, due to the degen 
eracy of the genetic code. For example, synthases of the 
present invention have a primary amino acid sequence. 
Degenerate synthase variations are different nucleic acid 
coding sequences that nevertheless encode the same primary 
amino acid sequence due to the degeneracy of the genetic 
code. 
“Expression” refers to transcription of a gene or nucleic 
acid molecule and the translation of that nucleic acid into a 
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polypeptide. Expression of genes also involves processing 
of RNA into mRNA in eukaryotic systems. It is not neces 
sary for the genes to integrate into the genome of a cell in 
order to achieve expression. This de?nition is not limited to 
expression in a particular system or a particular cell type and 
includes, Without limitation, stable, transient, in vitro, and in 
vivo expression. 
“Promoter” and “promoter regulatory element”, refers to 
a nucleic acid that is involved in controlling expression of a 
gene. Promoter regulatory elements, and the like, from a 
variety of sources can be used ef?ciently to promote gene 
expression. Promoter regulatory elements include 
constitutive, tissue-speci?c, developmental-speci?c, 
inducible, subgenomic promoters, and the like. Promoter 
regulatory elements may also include certain enhancer ele 
ments or silencing elements that improve or regulate tran 
scriptional ef?ciency. 
“Active Site” refers to a site in a terpene synthase that 
binds the hydrophobic portion of a terpene substrate, GPP, 
FPP, and/or GGPP. The active site can, under certain 
conditions, catalyZe a biosynthetic reaction that alloWs one 
or more reaction products to be produced. 
“Altered enZymatic speci?city” includes an alteration in 
the ability of a mutant synthase to use a particular terpene 
substrate or a change in the pro?le of reaction product(s) 
from a mutant synthase, compared to the substrate speci?c 
ity of and the reaction products made by a corresponding 
non-mutated synthase. Altered speci?city may include the 
ability of a synthase to exhibit different enZymatic param 
eters relative to a non-mutated synthase (Km, Vmax, etc), 
and/or to produce products that are different from those that 
are produced by a corresponding non-mutant synthase. 
“Structure coordinates” or “structural coordinates” refers 
to Cartesian coordinates (x, y, and Z positions) derived from 
mathematical equations involving Fourier synthesis as 
determined from patterns obtained via diffraction of a mono 
chromatic beam of X-rays by the atoms (scattering centers) 
of a synthase molecule in crystal form. Diffraction data are 
used to calculate electron density maps of repeating protein 
units in the crystal (unit cell). Electron density maps are used 
to establish the positions of individual atoms Within a 
crystal’s unit cell. The absolute values for structural coor 
dinates listed herein convey relative spatial relationships 
betWeen atoms because the absolute values ascribed to 
structural coordinates can be changed by rotational and/or 
translational movement along the x, y and/or Z axes, together 
or separately, While maintaining the same relative spatial 
relationships among atoms. Thus, a terpene synthase Whose 
absolute values for a set of structural coordinates can be 
rotationally or translationally adjusted to coincide With the 
particular values listed in Tables 1, 3, or 5 is considered to 
have the same structural coordinates as those of Tables 1, 3 
or 5. An example of structural coordinates that coincide With 
the absolute values listed herein after rotation and/or trans 
lation are the coordinates of Table 11. 
“Heavy atom derivatiZation” refers to a method of pro 
ducing a chemically modi?ed form of a synthase crystal. In 
practice, a crystal is soaked in a solution containing heavy 
atom salts or organometallic compounds, e. g., lead chloride, 
gold thiomalate, thimerosal, uranyl acetate and the like, 
Which can diffuse through the crystal and bind to the 
protein’s surface. Locations of the bound heavy atoms can 
be determined by X-ray diffraction analysis of the soaked 
crystal. The information is then used to construct phase 
information Which can then be used to construct three 
dimensional structures of the enZyme as described in 
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Blundel, T. L., and Johnson, N. L., Protein Crystallography, 
Academic Press (1976). 
“Unit cell” refers to a basic parallelepiped shaped block. 
Regular assembly of such blocks may construct the entire 
volume of a crystal. Each unit cell comprises a complete 
representation of the unit pattern, the repetition of Which 
builds up the crystal. 
“Mutagenesis” refers to the substitution of a different 
amino acid residue at a particular position in the primary 
amino acid sequence of a protein, thereby changing the 
R-group present at that position. Mutagenesis can be most 
easily performed by changing the coding sequence of a 
nucleic acid encoding the protein so that the coding 
sequence In the nucleic acid speci?es an amino acid residue 
different from the residue initially present at that position. 
“Space Group” refers to the arrangement of symmetry 
elements Within a crystal. 
“Molecular replacement” refers to the generation of a 
preliminary model of a synthase Whose structural coordi 
nates are unknoWn, by orienting and positioning a molecule 
Whose structural coordinates are knoWn Within the unit cell 
of the unknoWn crystal so as best to account for the observed 
diffraction pattern of the unknoWn crystal. Phases can then 
be calculated from this model and combined With the 
observed amplitudes to give an approximate Fourier syn 
thesis of the structure Whose coordinates are unknoWn. This 
in turn can be subject to any of the several forms of 
re?nement to provide a ?nal, accurate structure of the 
unknoWn crystal (Lattman, E., 1985, in Methods in 
EnZymology, 115:55—77; Rossmann, MG., ed., “The 
Molecular Replacement Method” 1972, Int. Sci. Rev. Ser., 
No. 13, Gordon & Breach, NeW York). Using structure 
coordinates and interatomic distance matrices, molecular 
replacement may be used to determine the structural coor 
dinates of a crystalline mutant, homologue, or a different 
crystal form of terpene synthase. 
“Recombinant protein” includes a protein that is chemi 
cally synthesiZed or derived biosynthetically from an iso 
lated gene. 
“Gene” includes naturally derived or genetically manipu 
lated nucleic acids that contain the information needed to 
produce a polypeptide. 
“Nucleic acid” includes any genetic material comprised of 
the nucleotides guanine, adenine, thymine, cytosine, uracil, 
inosine and the like. Nucleic acids may be single-, double-, 
or triple stranded. Nucleic acids may be deoxyribonucleic 
acid or ribonucleic acid. 
“Genetically manipulated” includes genes that have been 
modi?ed to contain a different nucleotide sequence from that 
present in a preselected nulceic acid. Genes can be manipu 
lated by synthetically or via traditional cloning, PCR, chemi 
cal gene synthesis, direct or random mutagenesis, and gene 
shuffling. Genetically manipulated also includes the process 
of making genes that are degenerate variations of nucleic 
acids encoding preselected proteins. 
“First domain” includes polypeptides having a ?rst and 
second end Wherein the ?rst end can have an amino terminal 
amino acid With a free amino group and can be linked by a 
peptide bond to a second amino acid. The ?rst end may also 
be modi?ed through acetylation and the like. The second end 
of the ?rst domain may or may not have a free carboxyl 
terminal group. 
“Second domain” includes polypeptides having a ?rst and 
second end Wherein the ?rst end can have an amino terminal 
amino acid and can be linked by a peptide bond to a second 
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amino acid. The second end of the second domain may or 
may not have a carboXyl terminal group. Typically, the ?rst 
end of the second domain is linked to the second end of the 
?rst domain via a peptide bond. 
“Isoprenoid substrate” refers to the C10, C15, and C20 
molecules, named geranyl diphosphate (GPP), farnesyl 
diphosphate (FPP), and geranylgeranyl diphosphate 
(GGPP), respectively. 
“Sequence identity” or “percent sequence identty” refers 
to the percentage of amino acids or nucleotides that occupy 
the same relative position When tWo protein sequences or 
nucleic acid sequences, a query sequence and a subject 
sequence, are aligned. The number of amino acid or nucle 
otide residues that are identical betWeen both the subject and 
query sequences are counted, divided by the number of 
residues in the query sequence, and multiplied by 100. The 
process is repeated until the alignment resulting in the 
highest percent sequence identity is found. Percent sequence 
identity can be determined by visual inspection and/or by 
using various computer programs, e.g., MegAlign 
(DNASTAR, Inc., Madison, Wis.) or BLAST programs 
available on the World Wide Web from the National Center 
for Biotechnology Information (NCBI). Gaps of one or more 
residues may sometimes be inserted to maXimiZe sequence 
alignments to structurally conserved domains of the query 
sequence, i.e., ot-helices, [3-sheets and loops. 
“Monoterpene product” refers to linear, cycliZed, and/or 
hydroXylated reaction products made from the substrate 
GPP. “Sesquiterpene product” refers to linear, cycliZed, 
and/or hydroXylated reaction products made from the sub 
strate FPP. “Diterpene product” refers to linear, cycliZed, 
and/or hydroXylated reaction products made from the sub 
strate GGPP. 
The present invention relates to terpene synthases and 
mutants thereof from Which the position of speci?c ot-carbon 
atoms and R-groups associated thereWith comprising the 
active site can be determined in three-dimensional space. 
The invention also relates to structural coordinates of the 
synthases, use of the structural coordinates to develop struc 
tural information related to synthase homologues, mutants, 
and the like, and to crystal forms of such synthases. 
Furthermore, the invention provides a method Whereby 
ot-carbon structural coordinates for atoms comprising the 
active site of a preselected terpene synthase can be used to 
develop syntheses in Which R-groups associated With active 
site ot-carbon atoms are different from the R-groups found in 
the preselected terpene synthase. In addition, the present 
invention provides for the production of novel terpene 
synthases based on the structural information provided 
herein and for the use of such synthases to make a variety of 
isoprenoid compounds. 
The present invention further provides, for the ?rst time, 
crystals of a synthase, as exempli?ed by tobacco 5epi 
aristolochene synthase (TEAS), Which are groWn in the 
presence or absence of substrate and substrate analogues, 
thus alloWing de?nition of the structural coordinates asso 
ciated thereWith. The structural coordinates alloW determi 
nation of the ot-carbon atoms comprising the active site and 
R-groups associated thereWith. The crystals of the present 
invention belong to the tetragonal space group P41212; the 
unit cell dimensions vary by a feW angstroms betWeen 
crystals but on average a=126 angstroms, c=122 angstroms, 
a=b, ot=90°, [3=90°, and y=90°. 
Structural coordinates are preferably obtained at a reso 
lution of about 2.2 to about 2.8 angstroms for a synthase in 
the presence and in the absence of bound substrate or 
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substrate analog. Coordinates for a synthase With a substrate 
analog bound in the active site are given in Table 10. 
Coordinates for a synthase in the absence of a substrate 
analog bound in the active site are given in Table 11. Those 
skilled in the art understand that a set of structure coordi 
nates determined by X-ray crystallography is not Without 
standard error. Therefore, for the purpose of this invention, 
any set of structure coordinates Wherein the active site 
ot-carbons of a synthase, synthase homologue, or mutants 
thereof, have a root mean square deviation less than 12.3 
angstroms When superimposed using the structural coordi 
nates listed in Table 1, 3, or 5, are considered identical. 
A schematic representation of the three-dimensional 
shape of a synthase is shoWn in FIG. 1 Which Was prepared 
by RIBBONS (Carson and Bugg, 1986, J. Mol. Graphics, 
4:121). The synthase shoWn in FIG. 1 consists entirely of 
a-helices and short connecting loops and turns, organiZed 
into ?rst and second structural domains. 
In one embodiment, an isolated synthase of the invention 
comprises siXteen active site ot-carbons having the structural 
coordinates of Table 3 and the relative distances 12.3 
angstroms of the distances given in Table 4. The active site 
ot-carbons of Table 3 generally are not all contiguous, i.e., 
are not adjacent to one another in the primary amino acid 
sequence of a synthase, due to intervening amino acid 
residues betWeen various active site ot-carbons. On the other 
hand, it should be appreciated that some of the active site 
ot-carbons can be adjacent to one another in some instances. 
In the embodiment depicted in the TEAS Y527F protein 
(SEQ ID N018), for example, active site ot-carbons are 
adjacent to one another in the primary amino acid sequence 
at positions 402, 403 and 404, respectively, Whereas active 
site ot-carbons at residues 273 and 294 are separated and 
thus are not adjacent. Thus, the numbering of active site 
ot-carbons given in Tables 1, 2, 3, 4, 5, or 6 is merely for 
convenience and such ot-carbons may reside at any position 
in the primary amino acid sequence that achieves the struc 
tural coordinates given in Tables 1, 3, or 5 and the relative 
interatomic distances 12.3 angstroms given in Tables 2, 4, or 
6. 
An appropriate combination of R-groups, linked to active 
site ot-carbons, can facilitate the formation of one or more 
desired reaction products. The combination of R-groups 
selected for use in a terpene synthase of the invention can be 
any combination other than the ordered arrangements of 
R-groups and corresponding active site ot-carbons shoWn in 
Tables 7, 8, or 9. An illustrative eXample of a suitable 
arrangement of R-groups and ot-carbons is Cys, Trp, lle, lle, 
Ser, Thr, Thr, Tyr, Leu, Cys, Val, Thr, Phe, Asp, Tyr and Thr, 
associated With active site ot-carbons 1 to 16, respectively, of 
Table 3. Another eXample of a suitable arrangement of 
R-groups and ot-carbons is Cys, Trp, lle, lle, Ser, Thr, Thr, 
Tyr, Leu, Cys, Val, Thr, Tyr, Asp, Phe, and Thr at active site 
alpha-carbons 1 to 16, respectively, of Table 3. In some 
embodiments, a synthase of the invention may have primary 
amino acid sequences as listed in SEQ ID NO:4, SEQ ID 
NO:6, SEQ ID NO:8, and SEQ ID NO:10, DNA molecules 
encoding the same, Which are listed in SEQ ID NO:3, SEQ 
ID NO:5, SEQ ID NO:7, and SEQ ID NO:9, respectively, 
and degenerate variations thereof. Typically, R-groups found 
on active site ot-carbons are those found in naturally occur 
ring amino acids. See, e.g., FIG. 2. In some embodiments, 
hoWever, R-groups other than naturally occurring amino 
acids can be used. 
Some arrangements of R-groups and active site ot-carbons 
result in mutant terpene synthases that form reaction prod 
ucts. Such enZymatically active synthases and their corre 
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sponding genes are useful to make known terpenoid 
hydrocarbons, e.g., monoterpenes such as pinene, sesquit 
erpenes such as delta-cadinene and diterpenes such as abi 
etadiene. Other enZymatically active synthases can be used 
to make novel terpenoid products. 
Some arrangements of R-groups and active site ot-carbons 
may result in mutant terpene syntheses that do not form 
reaction product(s) at a desired rate. Such syntheses and 
their genes are useful as controls in analyses of product 
formation by enZymatically active mutant synthases. Such 
synthases and their genes can also be useful in analyses of 
translation of enZymatically active mutant synthase genes, 
or as nutritional supplements. Such synthases can be 
attached to Sepharose beads and used for affinity puri?cation 
of isoprenoid compounds from crude preparations. In 
addition, such synthases and their genes can also be useful 
to develop reagents for various purposes, e.g., immunologi 
cal reagents to monitor expression of a terpene synthase 
protein or nucleic acid probes or primers to monitor inher 
itance of a terpene synthase gene in a plant breeding 
program. 
In some embodiments, the ot-carbon backbone of a syn 
thase ?rst domain aligns structurally With the catalytic core 
of glycosyl hydrolases, as exempli?ed by glucoamylase 
(Brookhaven Protein Database (PDB) code 3GLY) from 
Aspergillus awamori (Aleshin et al., 1994, J. Mol. Biol., 
238:575) and endoglucanase CelD (PDB code ICLC) from 
Clostridium thermocelum (Juy et al., 1992, Nature, 357:89), 
and the ot-carbon backbone of a synthase second domain, 
Which contains the active site, aligns structurally With avian 
farnesyl diphosphate synthase (FPS), Wherein the active site 
is comprised of 9, 16, or 19 amino acid residues With 
ot-carbon structural coordinates as listed in Tables 1, 3, or 5 
and interatomic distances as described in Tables 2, 4, or 6. 
Such ot-carbons have an ordered arrangement of R-groups 
different from that observed in a non-mutated synthase. 
In the present invention, the ?rst domain forms a tWisted 
a-barrel made up of eight short (10 to 15 amino acid 
residues) helices surrounding a surface cavity ?lled by 
ordered Water molecules When hydrated. The second domain 
comprises a tWo-layered barrel of ot-helices surrounding a 
hydrophobic and aromatic-rich active site pocket. Typically, 
the second domain contains a substrate binding site. As 
exempli?ed in FIG. 1, helix H is disrupted betWeen seg 
ments H1 and H2 by an amino acid such as proline, but its 
interhelical packing With helix G is accommodated by a 
corresponding kink in helix G betWeen G1 and G2. Within 
this kink, hydrogen bonds betWeen a hydroxyl group, such 
as that found on a threonine, and the carbonyl oxygen of 
other amino acids disrupt the main chain intrahelical hydro 
gen bonding of helix G thus assisting in producing the 
structure as determined. 
As exempli?ed by TEAS, terpene synthases of the present 
invention can have a ?rst domain segment comprising 
helices A and C (an A-C loop), and a second domain 
comprising helices J and K (a J-K loop) (FIG. 1). The 
ordering of these loops upon substrate binding results in a 
closed, solvent-inaccessible active site pocket. As the J-K 
loop becomes ordered, a lid-type structure is formed that 
clamps doWn over the active site entrance in the presence of 
substrate and an extended aromatic patch deep Within the 
active site pocket is formed. As the A-C loop becomes 
ordered, it translates inWard toWard the active site, position 
ing certain R groups in this loop at or near the active site. 
Thus, substrate binding to the active site results in a change 
in protein conformation. 
To identify or create mutant terpene synthases, sequence 
alignments can be performed to locate speci?c residues and 
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ot-carbons in a preselected polypeptide that have the struc 
tural coordinates and interatomic distances of Tables 1—2, 
3—4 or 5—6. The preselected polypeptide is used as the 
subject sequence in the alignment, e.g., the full-length 
primary amino acid sequence, a region 190 residues in 
length, a region 220 residues in length, or a region 300 
residues in length. The alignment can use residues 265 to 
535 of TEAS (SEQ ID NO: 2), Which includes the ot-carbons 
of Tables 1, 3 or 5, as the query sequence to align With the 
preselected polypeptide. The preselected polypeptide and 
the query sequence can be aligned using the BLASTp 2.0.9 
computer program With a BLOSUM 62 scoring matrix, an 
expect value of 10, a gap open value of 11, an xidropoff 
value of 50, a gap extension value of 1, a WordsiZe of 3 and 
no ?ltering of loW complexity sequences. As an alternative, 
the BLASTp 2.0.9 program can be used With a BLOSUM 50 
scoring matrix, an expect value of 10, a gap open value 13, 
an xidropoff value of 50, a gap extension value of 2, a 
WordsiZe of 3 and no ?ltering of loW complexity sequences. 
Other parameter values can also be used, e.g., a gap exten 
sion value from 0 to 4. See Altschul, et al., Nucl. Acids Res. 
25:3389—3402. 
Regions of the preselected polypeptide With signi?cant 
sequence identity to residues 265—535 of TEAS, e.g., 20% 
or greater sequence identity, 25% or greater sequence 
identity, 35% or greater sequence identity, 40% or greater 
sequence identity, 50% or greater sequence identity, 60% or 
greater sequence identity, 70% or greater sequence identity, 
or 80% or greater sequence identity are examined for 
speci?c residues that align With the TEAS residues corre 
sponding to those listed in Tables 1, 3, or 5. In some cases, 
the output of the computer program alignment identi?es a 
speci?c residue in the preselected polypeptide for each of 
the nine, sixteen, or nineteen residues in the query sequence 
having the structural coordinates and interatomic distances 
of Tables 1—2, 3—4 or 5—6, With or Without gaps introduced 
by the alignment program. In other cases, a gap is introduced 
by the alignment program in either the query sequence or the 
subject sequence such that no direct alignment or a mis 
alignment occurs betWeen one or more of the nine, sixteen, 
or nineteen residues in the query sequence that ate of interest 
In either case, the output can be visually inspected, and 
speci?c residues can be chosen in the subject sequence after 
adjusting the alignment so that alpha-helices and beta-sheet 
regions in the query sequence are maintained and that gaps 
or insertions in the subject sequence align With loop regions 
of the query sentence. 
Sequence alignments suggest that other terpene synthases 
have regions With 20% or greater sequence identity to 
residues 265—535 of TEAS. Therefore, a region of a terpene 
synthase other than TEAS can be used as the query 
sequence, e.g., regions of terpene synthases given in SEQ ID 
NOS: 4, 6, 8, 10, 12, 20, 22, 24, 26, 28, 30, 32, 34—40, 42, 
44, 46, 48, 50, 52, 54, 56, or 58, that have signi?cant 
sequence identity to residues 265—535 of SEQ ID NO: 2. For 
example, large sequence insertions are present at the amino 
terminus in taxadiene synthase (SEQ ID NO: 44) With 
respect to TEAS, or are Within solvent-exposed loops in the 
amino-terminal domain. Thus, regions of taxadiene synthase 
With greater than 20% sequence identity to SEQ ID NO: 2 
are closer to the carboxy-terminal end, e.g., from residue 
579 to residue 847 of SEQ ID NO: 44. 
Useful regions of other terpene synthases that can be used 
as the query sequence include, Without limitation, residues 
343 to 606 of SEQ ID NO: 20, 316 to 586 of SEQ ID NO: 
22, residues 352 to 622 of SEQ ID NO: 58, residues 272 to 
540 encoded by SEQ ID NO: 33, residues 319 to 571 of SEQ 
US 6,645,762 B2 
21 
ID NO: 42, residues 579 to 847 of SEQ ID NO: 44, residues 
495 to 767 of SEQ ID NO: 46, residues 295 to 564 of SEQ 
ID NO: 48, residues 307 to 578 of SEQ ID NO: 50, residues 
264 to 533 of SEQ ID NO: 52, residues 585 to 853 of SEQ 
ID NO: 56, residues 307 to 574 of SEQ ID NO: 54, residues 
309 to 577 of SEQ ID NO: 24, residues 315 to 584 of SEQ 
ID NO: 26, residues 265 to 536 of SEQ ID NO: 28, residues 
342 to 612 of SEQ ID NO: 30 and residues 273 to 541 of 
SEQ ID NO: 32. 
One or more of the speci?c residues in the subject 
sequence that align With residues in the query sequence are 
mutated in the preselected polypeptide, e.g, by making 
mutations in a nucleic acid encoding the polypeptide. The 
mutant terpene synthase thus created can then be expressed 
in a host cell and the protein evaluated for enZymatic 
activity, if desired. 
Mutant proteins of the present invention may be prepared 
in a number of Ways including but not limited to 
oligonucleotide-directed mutagenesis, deletion, chemical 
mutagenesis, and the like. One or more R-groups associated 
With the active site ot-carbon atoms in a terpene synthase are 
changed by altering the nucleotide sequence of the corre 
sponding gene. For example, a mutation can be introduced 
into SEQ ID NO:1, the nucleotide sequence for TEAS, at 
codons encoding one or more of the folloWing sixteen 
ot-carbons: ot-carbon 1=Cys 270; ot-carbon 2=Trp 273; 
ot-carbon 3=lle 294; ot-carbon 4=lle 297; ot-carbon 
5=Ser298; ot-carbon 6=Thr 402; ot-carbon 7=Thr 403; 
ot-carbon 8=Tyr 404; ot-carbon 9=Leu 407; ot-carbon 
10=Cys 440; ot-carbon 11=Val 516; ot-carbon 12=Thr 519; 
ot-carbon 13=Tyr 520; ot-carbon 14=Asp 525; ot-carbon 
15=Tyr 527; or ot-carbon 16=Thr 528. The protein encoded 
by the mutant gene is then produced by expressing the gene 
in, for example, a bacterial or plant expression system. 
Alternatively, synthase mutants may be generated by site 
speci?c replacement of a particular amino acid With an 
unnaturally occurring amino acid. As such, synthase mutants 
may be generated through replacement of an amino acid 
residue or a particular cysteine or methionine residue With 
selenocysteine or selenomethionine. This may be achieved 
by groWing a host organism capable of expressing either the 
Wild-type or mutant polypeptide on a groWth medium 
depleted of natural cysteine or methionine or both and 
groWing on medium enriched With either selenocysteine, 
selenomethionine, or both. These and similar techniques are 
described in Sambrook et al., (Molecular Cloning, A Labo 
ratory Manual, 2” Ed. (1989) Cold Spring Harbor Labora 
tory Press). 
Another suitable method of creating mutant synthases of 
the present invention is based on a procedure described in 
Noel and Tsal (1989) J. Cell. Biochem., 40:309—320. In so 
doing, the nucleic acid encoding the synthase can be syn 
thetically produced using oligonucleotides having overlap 
ping regions, the oligonucleotides being degenerate at spe 
ci?c bases so that mutations are induced. 
According to the present invention, nucleic acid 
sequences encoding a mutated synthase can be produced by 
the methods described herein, or any alternative methods 
available to the skilled artisan. In designing the nucleic acid 
sequence (gene) of interest, it may be desirable to reengineer 
the gene for improved expression in a particular expression 
system. For example, it has been shoWn that many bacteri 
ally derived genes do not express Well in plant systems. In 
some cases, plant derived genes do not express Well in 
bacteria. This phenomenon may be due to the non-optimal 
G+C content or A+T content of the gene relative to the 
expression system being used. For example, the very loW 
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G+C content of many bacterial genes results in the genera 
tion of sequences mimicking or duplicating plant gene 
control sequences that are highly A+T rich. The presence of 
A+T rich sequences Within the genes introduced into plants 
(e.g., TATA box regions normally found in gene promoters) 
may result in aberrant transcription of the gene(s). In 
addition, the presence of other regulatory sequences residing 
in the transcribed mRNA (e.g. polyadenylation signal 
sequences (AAUAAA) or sequences complementary to 
small nuclear RNAs involved in pre-mRNA splicing) may 
lead to RNA instability. Therefore, one goal in the design of 
genes is to generate nucleic acid sequences that have a G+C 
content that affords mRNA stability and translation accuracy 
for a particular expression system. 
Due to the plasticity afforded by the redundancy of the 
genetic code (i.e., some amino acids are sled by more than 
one codon), evolution of the genomes of different organisms 
or classes of organisms has resulted in differential usage of 
redundant codons. This “codon bias” is re?ected in the mean 
base composition of protein coding regions. For example, 
organisms With relatively loW G+C contents utiliZe codons 
having A or T in the third position of redundant codons, 
Whereas those having higher G+C contents utiliZe codons 
having G or C in the third position. Therefore, in reengi 
neering genes for expression, one may Wish to determine the 
codon bias of the organism in Which the gene is to be 
expressed. Looking at the usage of the codons as determined 
for genes of a particular organism deposited in GenBank can 
provide this information. After determining the bias thereof, 
the neW gene sequence can be analyZed for restriction 
enZyme sites as Well as other sites that could affect tran 
scription such as exon:intron junctions, polyA addition 
signals, or RNA polymerase termination signals. 
Genes encoding syntheses can be placed in an appropriate 
vector, depending on the artisan’s interest, and can be 
expressed using a suitable expression system. An expression 
vector, as is Well knoWn in the art, typically includes 
elements that permit replication of said vector Within the 
host cell and may contain one or more phenotypic markers 
for selection of cells containing said gene. The expression 
vector Will typically contain sequences that control expres 
sion such as promoter sequences, ribosome binding sites, 
and translational initiation and termination sequences. 
Expression vectors may also contain elements such as 
subgenomic promoters, a repressor gene or various activator 
genes. The artisan may also choose to include nucleic acid 
sequences that rest at in secretion of the gene product, 
movement of said product to a particular organelle such as 
a plant plastid (see US. Pat. Nos. 4,762,785; 5,451,513 and 
5,545,817), or other sequences that increase the ease of 
peptide puri?cation, such as an af?nity tag. 
AWide variety of expression control sequences are useful 
in expressing mutated synthases When operably linked 
thereto. Such expression control sequences include, for 
example, the early and late promoters of SV40 for animal 
cells, the lac system, the trp system, major operator and 
promoter systems of phage )t, and the control regions of coat 
proteins, particularly those from RNA viruses in plants. In E. 
coli, a useful transcriptional control sequence is the T7 RNA 
polymerase binding promoter, Which can be incorporated 
into a pET vector as described by Studier et al., (1990) 
Methods EnZymology, 185:60—89. 
For expression, a desired gene should be operably linked 
to the expression control sequence and maintain the appro 
priate reading frame to permit production of the desired 
synthase. Any of a Wide variety of Well-knoWn expression 
vectors are of use in the present invention. These include, for 
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example, vectors consisting of segments of chromosomal, 
non-chromosomal and synthetic DNA sequences such as 
those derived from SV40, bacterial plasmids (including 
those from E. coli such as col E1, pCR1, pBR322 and 
derivatives thereof, pMB9), Wider host range plasmids such 
as RP4, phage DNA such as phage )t, NM989, M13, and 
other such systems as described by Sambrook et al., 
(Molecular Cloning, A Laboratory Manual, 2”d Ed. (1989) 
Cold Spring Harbor Laboratory Press). 
A Wide variety of host cells are available for expressing 
synthase mutants of the present invention. Such host cells 
include, Without limitation, bacteria such as E. coli, Bacillus 
and Streptomyces, fungi, yeast, animal cells, plant cells, 
insect cells, and the like. Preferred embodiments of the 
present invention include terpene synthase mutants that are 
expressed in E. coli or in plant cells. Said plant cells can 
either be in suspension culture or a culture on a solid support 
such as an agar-based medium. 
Genes encoding synthases of the present invention can 
also be expressed in transgenic plant cells. In order to 
produce transgenic plants, vectors containing a nucleic acid 
construct encoding a mutant terpene synthase are inserted 
into the plant genome. Preferably, these recombinant vectors 
are capable of stable integration into the plant genome. One 
variable in making a transgenic plant is the choice of a 
selectable marker gene. A selectable marker gene is used to 
identify transformed cells against a high background of 
untransformed cells. Such selectable marker genes include 
but are not limited to aminoglycoside phosphotransferase 
gene of transposon Tn5 (Aph II) Which encodes resistance to 
the antibiotics kanamycin, neomycin, and G418, as Well as 
those genes Which encode for resistance or tolerance to 
glyphosate, hygromycin, methotrexate, phosphinothricin, 
imidaZolinones, sulfonylureas, and triaZolophyrimidine 
herbicides, such as chlorosulfuron, bromoxynil, dalapon and 
the like. In addition to a selectable marker gene, it may be 
desirable to use a reporter gene. In some instances a reporter 
gene may be used With a selectable marker. Reporter genes 
alloW the detection of transformed cell and may be used at 
the discretion of the artisan. A list of these reporter genes is 
provided in K. Weising et al., 1988, Ann. Rev. Genetics, 
22:421. 
The genes are expressed either by promoters expressing in 
all tissues at all times (constitutive promoters), by promoters 
expressing in speci?c tissues (tissue-speci?c promoters), 
promoters expressing at speci?c stages of development 
(developmental promoters), and/or promoter expression in 
response to a stimulus or stimuli (inducible promoters). The 
choice of these is at the discretion of the artisan. 
Several techniques exist for introducing foreign genes 
into plant cells, and for obtaining plants that stably maintain 
and express the introduced gene. Such techniques include 
acceleration of genetic material coated directly into cells 
(US. Pat. No. 4,945,050). Plant may also be transformed 
using Agrobacterium technology (US. Pat. Nos. 5,177,010, 
5,104,310, 5,149,645, 5,469,976, 5,464,763, 4,940,838, 
4,693,976, 5,591,616, 5,231,019, 5,463,174, 4,762,785, 
5,004,863, and 5,159,135; European Patent Applications 
116718, 290799, 320500, 604662, 627752, 0267159, and 
0292435. Other transformation technologies include Whis 
kers technology, see US. Pat. Nos. 5,302,523 and 5,464, 
765. Electroporation technology has also been used to 
transform plants, see WO 87106614, WO 92109696 and 
WO 93121335 and US. Pat. Nos. 5,472,869 and 5,384,253. 
Viral vector expression systems can also be used such as 
those described in US. Pat. Nos. 5,316,931, 5,589,367, 
5,811,653, and 5,866,785. 
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In addition to numerous technologies for transforming 
plants, the type of tissue that is contacted With the genes of 
interest may vary as Well. Suitable tissue includes, but is not 
limited to, embryogenic tissue, callus tissue, hypocotyl, 
meristem and the like. Almost all plant tissues may be 
transformed during dedifferentiation using the appropriate 
techniques described herein. 
Regardless of the transformation system used, a gene 
encoding a mutant synthase is preferably incorporated into 
a gene transfer vector adapted to express said gene in a plant 
cell by including in the vector an expression control 
sequence (plant promoter regulatory element). In addition to 
plant promoter regulatory elements, promoter regulatory 
elements from a variety of sources can be used ef?ciently in 
plant cells to express foreign genes. For example, promoter 
regulatory elements of bacterial origin, such as the octopine 
synthase promoter, the nopaline synthase promoter, the 
mannopine synthase promoter may be used. Promoters of 
viral origin, such as the cauii?oWer mosaic virus (35S and 
19S) are also desirable. Plant promoter regulatory elements 
also include, but are not limited to, ribulose-1,6 
bisphosphate carboxylase small subunit promoter, beta 
conglycinin promoter, phaseolin promoter, ADH promoter, 
heat-shock promoters, and tissue speci?c promoters and the 
like. Numerous promoters are available to skilled artisans 
for use at their discretion. 
It should be understood that not all expression vectors and 
expression systems function in the same Way to express the 
mutated gene sequences of the present invention. Neither do 
all host cells function equally Well With the same expression 
system. HoWever, one skilled in the art may make a selection 
among these vectors, expression control sequences, and host 
Without undue experimentaton and Without departing from 
the scope of this invention. 
Once a synthase of the present invention is expressed, the 
protein obtained therefrom can be puri?ed so that structural 
analysis, modeling, and/or biochemical analysis can be 
performed, as exempli?ed herein. The nature of the protein 
obtained can be dependent on the expression system used. 
For example, genes, When expressed in mammalian or other 
eukaryotic cells, may contain latent signal sequences that 
may result in glycosylation, phosphorylation, or other post 
translational modi?cations, Which may or may not alter 
function. Once the proteins are expressed, they can be easily 
isolated and puri?ed using techniques common to the person 
having ordinary skill in the art of protein biochemistry and 
as described in Colligan et al., (1997) Current Protocols in 
Protein Science, Chanda, V. B., Ed., John Wiley & Sons, Inc. 
Such techniques often include the use of cation-exchange or 
anion-exchange chromatography, gel ?ltration-siZe exclu 
sion chromatography, and the like. Another technique that 
may be commonly used is affinity chromatography. Affinity 
chromatography can include the use of antibodies, substrate 
analogs, or histidine residues (His-tag technology). 
Once puri?ed, mutants of the present invention may be 
characteriZed by any of several different properties. For 
example, such mutants may have altered active site surface 
charges of one or more charge units. In addition, the mutants 
may have an altered substrate speci?city or spectrum of 
reaction product relative to a non-mutated synthase. 
The present invention alloWs for the characteriZation of 
mutant terpene synthase by crystalliZation folloWed by 
X-ray diffraction. Polypeptide crystalliZation occurs in solu 
tions Where the polypeptide concentration exceeds it solu 
bility maximum (i.e., the polypeptide solution is 
supersaturated). Such solutions may be restored to equilib 
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rium by reducing the polypeptide concentration, preferably 
through precipitation of the polypeptide crystals. Often 
polypeptides may be induced to crystalliZe from supersatu 
rated solutions by adding agents that alter the polypeptide 
surface charges or perturb the interaction betWeen the 
polypeptide and bulk Water to promote associations that lead 
to crystalliZation. 
Compounds knoWn as “precipitants” are often used to 
decrease the solubility of the polypeptide in a concentrated 
solution by forming an energetically unfavorable precipitat 
ing depleted layer around the polypeptide molecules (Weber, 
1991, Advances in Protein Chemistry, 41:1—36). In addition 
to precipitants, other materials are sometimes added to the 
polypeptide crystalliZation solution. These include buffers to 
adjust the pH of the solution and salts to reduce the solubility 
of the polypeptide. Various precipitants are knoWn in the art 
and include the folloWing: ethanol, 3-ethyl-2-4 pentanediol, 
and many of the polyglycols, such as polyethylene glycol. 
Commonly used polypeptide crystalliZation methods 
include the folloWing techniques: batch, hanging drop, seed 
initiation, and dialysis. In each of these methods, it is 
important to promote continued crystalliZation after nucle 
ation by maintaining a supersaturated solution. In the batch 
method, polypeptide is mixed With precipitants to achieve 
supersaturation, the vessel is sealed and set aside until 
crystals appear. In the dialysis method, polypeptide is 
retained in a sealed dialysis membrane that is placed into a 
solution containing precipitant. Equilibration across the 
membrane increases the polypeptide and precipitant con 
centrations thereby causing the polypeptide to reach super 
saturation levels. 
In the preferred hanging drop technique (McPherson, 
1976, J. Biol. Chem., 6300—6306), an initial polypeptide 
mixture is created by adding a precipitant to a concentrated 
polypeptide solution. The concentrations of the polypeptide 
and precipitants are such that in this initial form, the 
polypeptide does not crystalliZe. Asmall drop of this mixture 
is placed on a glass slide that is inverted and suspended over 
a reservoir of a second solution. The system is then sealed. 
Typically, the second solution contains a higher concentra 
tion of precipitant or other dehydrating agent. The difference 
in the precipitant concentrations causes the protein solution 
to have a higher vapor pressure than the solution. Since the 
system containing the tWo solutions is sealed, an equilibrium 
is established, and Water from the polypeptide mixture 
transfers to the second solution. This equilibrium increases 
the polypeptide and precipitant concentration in the 
polypeptide solution. At the critical concentration of 
polypeptide and precipitant, a crystal of the polypeptide may 
form. 
Another method of crystalliZation introduces a nucleation 
site into a concentrated polypeptide solution.(Generally, a 
concentrated polypeptide solution is prepared and a seed 
crystal of the polypeptide Is introduced into this solution. If 
the concentration of the polypeptide and any precipitants are 
correct, the seed crystal Will provide a nucleation site around 
Which larger crystal forms. In preferred embodiments, the 
crystals of the present invention are formed in hanging drops 
With 15% PEG 8000; 200 mM magnesium acetate or mag 
nesium chloride, 100 mM 3-(N-morpholino)-2 
hydroxypropanesulfonic acid (pH 7.0), 1 mM dithiothreitol 
as precipitant. 
Some proteins may be recalcitrant to crystalliZation. 
HoWever, several techniques are available to the skilled 
artisan to induce crystalliZation. The removal of polypeptide 
segments at the amino or carboxyl terminal end of the 
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protein may facilitate production of crystalline protein 
samples. Removal of such segments can be done using 
molecular biology techniques or treatment of the protein 
With proteases such as trypsin, chymotrypsin, subtilisin. 
Such procedures can result in the removal of ?exible 
polypeptide segments that may negatively affect crystalli 
Zation. 
The crystals so produced have a Wide range of uses. For 
example, high quality crystals are suitable for X-ray or 
neutron diffraction analysis to determine the three 
dimensional structure of a mutant synthase and to design 
additional mutants thereof. In addition, crystalliZation can 
serve as a further puri?cation method. In some instances, a 
polypeptide or protein Will crystalliZe from a heterogeneous 
mixture into crystals. Isolation of such crystals by ?ltration, 
centrifugation, etc., folloWed by redissolving the polypep 
tide affords a puri?ed solution suitable for use in groWing the 
high-quality crystals needed for diffraction studies. The 
high-quality crystals may also be dissolved in Water and then 
formulated to provide an aqueous solution having other uses 
as desired. 
Because synthases may crystalliZe in more than one 
crystal form, the structural coordinates of Carbons of an 
active site determined from a synthase or portions thereof, as 
provided by this invention, are particularly useful to solve 
the structure of other crystal forms of synthases. The struc 
tural coordinates, as provided herein, may also be used to 
solve the structure of synthases having ot-carbons position 
Within the active sites in a manner similar to the Wild-type 
yet having R-groups that may or may not be identical. 
Furthermore, the structural coordinates disclosed herein may 
be used to determine the structure of the crystalline form of 
other proteins With signi?cant amino acid or structural 
homology to any functional domain of a synthase. One 
method that may be employed for such purpose is molecular 
replacement. In this method, the unknoWn crystal structure, 
Whether it is another crystal form of a synthase, a synthase 
having a mutated active site, or the crystal of some other 
protein With signi?cant sequence identity and/or structural 
homology of a synthase may be determined using the 
coordinates given in Tables 10 and/or 11. This method 
provides suf?cient structural form for the unknoWn crystal 
more efficiently than attempting to determine such informa 
tion ab initio. In addition, this method can be used to 
determine Whether or not a given synthase in question falls 
Within the scope of this invention. 
As further disclosed herein, synthases and mutants thereof 
may be crystalliZed in the presence or absence of substrates 
and substrate analogs. The crystal structures of a series of 
complexes may then be solved by molecular replacement 
and compared to that of the Wild-type to assist in determi 
nation of suitable replacements for R-groups Within the 
active site, thus making synthase mutants according to the 
present invention. 
All mutants of the present inventions may be modeled 
using the information disclosed herein Without necessarily 
having to crystalliZe and solve the structure for each and 
every mutant. For example, one skilled in the art may use 
one of several specialiZed computer programs to assist in the 
process of designing synthases having mutated active sites. 
Examples of such programs can be as folloWs: GRID 
(Goodford, 1985, J. Med. Chem., 28:849—857); MCSS 
(Miranker and Karplus, 1991, Proteins: Structure, Function 
and Genetics, 11:29—34); AUTODOCK (Goodsell and 
Olsen, 1990, Proteins: Structure, Function, and Genetics, 
8:195—202); and DOCK (KuntZ et al., 1982, J. Mol. Biol., 
161:269—288). In addition, speci?c computer programs are 
US 6,645,762 B2 
27 28 
also available to evaluate, speci?c substrate-active site inter 
actions and the deformation energies and electrostatic inter 
actions resulting therefrom. MODELLER is a computer 
GCTAGTGTAATTATGGCGAGTTATCGATGAC (Sense) (SEQ ID NO: 15 ) and 
GTCATCGATAACTCGCCATATAATTACACTAGC (antisense) (SEQ ID NO: 16 ) . 
program often used for homology or comparative modeling 1O TEAS W273S/C440W 
of the three-dimensional structure of a protein. A. Sali & T. IIllltaIllt Was (POHSIItIIlCIfIdfIOIII 
L. Blundell. J.Mo1.Bio1. 234, 779%15, 1993. Apreselected a _ -P _ + temp ate 115mg t @ Pnmers 
polypeptide sequence to be modeled is aligned With one or descnbed for generatloh of TEAS C440W‘ 
TEAS 406/407 random library 
more terpene synthases Whose crystal structures are knoWn 15 For generation of a library of TEAS mutants With random 
ahd the MODELLER Program is used to Calculate a hlh- amino acids at positions 406 and 407, tWo 50 microliter 
atom model, based on optimum satisfaction of spatial QuickChange reactions Were carried out With the TEAS 
restraints. Such restraints can include, inter alia, homolo- pET28b(+) template and the primers 
GCACTAGCAACTACCACATATTACNNSNNSGCGACAACATCGTATTTGGGCATG (sense) (SEQ ID NO:l7) and 
CATGCCCAAATACGATGTTGTCGCSNNSNNGAATATGTGGTAGTTGCTAGTGC (antisense) (SEQ ID NO: 18 ) , 
gous structures, ?uorescence spectroscopy, NMR 25 in Which N denotes A, C, G, or T and S denotes C or G. By 
experiments, or atom-atom potentials of mean force. this choice of nucleotides, the reaction included primers 
The present invention enables synthase mutants to be Which coded for all possible amino acid combinations at 
made and crystal structures thereof to be solved. Moreover, positions 406 and 407. No adjustment Was made for differ 
by virtue of the present invention, the location of the active ing numbers of codons among amino acids In Order to 
_Site ehd t_he ihterfaee of Substrate therewith Perhht the 30 ensure efficient reactions, and to minimiZe the preference for 
ldehtlheatloh of eeslrable Rjgreups fer thutagehes1s~ The hybridiZation of Wild-type primers to the template, the 
particular embodiments of this invention are further exem- primers Were designed to be longer than those used to 
phhed 1h, the Example/S- However’,those skhled In the, art generate the mutations described above. In addition, they 
Wlh readhy apprhclate thatthe sheclhc experhhehts detahed Were HPLC puri?ed prior to use. After 18 cycles of plasmid 
are only illustrative of the invention as described more fully Copying the reaction Was incubated for two hours With 
m the Chums’ Whlch follow thereafter' 35 Dpnl, ethanol precipitated, and redissolved in 5 microliters 
EXAMPLE 1 Water. Each of four 40 microliter aliquots of E. coli Nov 
Generation of Mutant TEAS Genes aBlue (Novagen) cells Were electroporated With 1.5 micro 
liters of the redissolved DNA. After a recovery period, the 
cells Were plated on kanamycin-LB-agar plates. In order to 
Change method (Stratagene) M anufa Cm r e r, S instructions 40 transfer the neWly constructed plasm1ds to expression cells, 
Were folloWed, except as noted. Mutations Were con?rmed the Colonies Were scraped frhth _ah_fohr plates; and use? to 
by DNA sequencing, and plasmids containing the desired Start ah 8 thL Culture grOWh 1h hqhld LB Ihedhhh at 37 0 
Construct Generation and Expression 
All mutant enZymes Were constructed by the Quick 
mutation were used to transform BL_21(DE3) expression for 8 hours. Plasmid puri?ed from this culture Was used to 
cells. Protein Was expressed, puri?ed, and stored at —80° C. transform 20 microliters of eothpeteht BL'21(DE3) eehs 
TEAS W273S 45 For storage of the constructs, each individual colony Was 
The TEAS W273S mutant Was generated from a TEAS- used to inoculate 100 microliters of LB medium containing 
pET28b(+) template using the folloWing primers: kanamycin (50 micrograms/mL) in 96-well culture plates. 
GTTGAATGCTACTTTTCGGCATTAGGAGTTTAT (sense) (SEQ ID NO:13) and 
ATAAACTCCTAATGCCGAAAAGTAGCATTCAAC (antisense) (SEQ ID NO:14 ) . 
Mutagenesis Was carried out according to the manufactur- 55 The cells Were groWn at 37° C. until the A600 reached 
er’s instructions, except that sense and antisense strands approximately Ohe; 100 microliters of 30% glyeegol in LB 
Were generated in separate reactions. For each, 30 plasmid- were then added’ and the ptates were frozen at _8_ Set 
- - - o of randomly selected colonies Were groWn from individual 
copying cycles of one minute, annealing at 55 C. and 16 
. . 68° C _ d Th glycerol stocks of some colonies, and plasmids Were 
mmutes extehsloh at ' Were Came out‘ 6 tWO extracted for sequencing. Approximately 30 percent of the 
reaction IIliXtllreS Were then combined, heated to 95° C for 60 colonies Were found to be Wild-type. Nucleotide and amino 
2.5 minutes, and cooled to room temperature before Dpnl acid sequences for TEAS 406/407 mutant genes and proteins 
treatment. are shoWn in SEQ ID NOS:11 and 12. 
TEAS Y520F 
TEAS C440W The tyrosine residue at position 520 of SEQ ID No:2 Was 
65 changed to a phenylalanine residue by site-directed 
The TEAS C440W mutant Was generated from the TEAS- mutagenesis With primers, in a manner similar to that 
pET28b(+) template using the folloWing primers: described above. For Y520F the TAT codon Was changed to 
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TTC. The nucleotide sequence of the mutant gene is shown 
in SEQ ID No:5. 
TEAS Y527F 
The tyrosine residue at position 527 of SEQ ID No:2 Was 
changed to a phenylalanine residue by site-directed 
mutagenesis With primers, in a manner similar to that 
described above. For Y527F, the TAC codon at position 527 
of the TEAS amino acid sequence Was changed to TTC. The 
nucleotide sequence of the mutant TEAS Y527F gene is 
shoWn in SEQ ID No: 7. 
TEAS W273E 
The tryptophan residue at position 273 of SEQ ID No:2 
Was changed to a phenylalanine residue by site-directed 
mutagenesis With primers, in a manner similar to that 
described above. For W273E, the TGG codon at position 
273 of the TEAS amino acid sequence Was changed to GAG. 
The nucleotide sequence of the mutant gene is shoWn in 
SEQ ID No.13. 
EXAMPLE 2 
Expression and Isolation of Synthase Polypeptides 
Unless otherWise noted, mutated and non-mutated TEAS 
proteins Were expressed in Escherichia coli, puri?ed by 
metal chelation, anion exchange, and gel ?ltration chroma 
tography. 
Constructs of TEAS and mutant TEAS proteins in the 
vector pET-28b(+) (Novagen) Were expressed in E. coli 
cells. For a typical protein preparation of any of these 
enZymes, E. coli strain BL21(DE3) cells containing the 
plasmid construct Were groWn at 37° C. in 4><1L terri?c 
broth to an A6OO=1.0. The temperature Was dropped to 22° 
C., and protein expression Was induced by adding IPTG to 
a ?nal concentration of 0.1 mM. After 15—20 h, the cells 
Were harvested by centrifugation, resuspended in 5 mL 
bufferA(20 mM Tris, 500 mM NaCl, 20 mM imidaZole, pH 
7.9) per 1 g cells (Wet Weight), and stirred for 0.5 h at 4° C. 
The cells Were then lysed by sonication, and the resulting 
lysate Was centrifuged for 0.7 h at 82,000><g. The 
supernatant, containing the protein, Was loaded over a 2—3 
mL Ni2+ chelating histidine af?nity column (Qiagen) equili 
brated in buffer A, and the column Was Washed With addi 
tional buffer A until the A200 of the eluent returned to 
baseline. The protein Was then eluted With a 20—200 mM 
imidaZole gradient in buffer A. Protein-containing fractions 
Were pooled and dialyZed against buffer B (50 mM HEPES, 
5 mM MgCl2, 1 mM DTT), then loaded onto an 8 mL 
MonoQ cation-exchange column (Pharmacia). The column 
Was Washed With 20 column volumes buffer B, and the 
protein Was eluted With a 0—500 mM NaCl gradient in buffer 
B. The resulting protein Was further puri?ed by gel ?ltration 
on a Superdex-200 column (Pharmacia) in 50 mM Tris, 100 
mM NaCl, 5 mM MgCl2, 1 mM DTT, pH 8.0. Puri?ed 
protein Was then dialyZed against 5 mM Tris, 5 mM NaCl, 
1 mM DTT, pH 8.0, concentrated to 18—22 mg/mL, and 
stored at —80° C. in 1000 L aliquots until needed. 
EXAMPLE 3 
CrystalliZation and Structural Analysis of Synthase 
Polypeptides 
Crystal GroWth and Microseeding 
All crystalliZation attempts Were carried out by the 
hanging-drop vapor diffusion method. Concentrated protein 
Was mixed With an equal volume (2—5 uL each) of reservoir 
solution on a plastic cover slip. The cover slip Was then 
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inverted over a Well of a plastic 24-Well tissue culture plate, 
containing 0.5—1.0 mL of reservoir solution, and sealed by 
a layer of vacuum grease betWeen the Well and cover slip. 
The plates Were incubated at 4° C. While the protein con 
centration in the hanging drop sloWly increased by vapor 
diffusion. Approximately 300 different reservoir solutions, 
ranging pH 4.5—9 With a variety of precipitants and added 
salts, Were assayed for crystalliZation of TEAS (SEQ ID 
NO:2). TEAS crystalliZed With a reservoir solution of 15% 
PEG 8000, 100 mM MOPSO (3-[N-morpholino]-2 
hydroxypropanesulfonic acid), 200 mM magnesium acetate, 
1 mM DTT, pH 6.9—7.3. For microseeding, an existing 
crystal Was crushed in a feW uL of precipitant solution, then 
diluted to 50 microliters. After initial centrifugation to 
remove large particles, the suspension Was serially diluted 
With additional precipitant solution, and a small volume of 
a diluted seed stock Was added to each neW crystalliZation 
drop. For macroseeding, crystals Which Were no longer 
rapidly groWing (usually 2 Weeks after drops Were set up), 
Were “rinsed” by serially transferring them through tWo to 
three drops of reservoir solution. The crystal Was then 
transferred to a fresh drop containing protein and reservoir 
solution, and equilibrated against a reservoir solution as in 
the initial groWth. Individual crystals varied in their degree 
of internal order. In some cases, several crystals Were 
screened to identify a Well-diffracting crystal With loW 
mosaicity. 
Data Collection 
Prior to data collection, crystals Were transferred to a drop 
of reservoir solution, or reservoir solution containing a 
compound to be soaked into the crystal A small volume of 
cryoprotectant solution (15% PEG8000, 100 mM MOPSO, 
200 mM Mg acetate, 20% ethylene glycol, 1 mM DTT, pH 
7) Was then added to the drop. After a short equilibration 
time (1—5 minutes), the crystal Was transferred to a drop of 
cryoprotectant, or cryoprotectant With soaking compound 
added. After another short equilibration time, the crystal Was 
picked up on a nylon loop, and quickly mounted for data 
collection in a stream of cold nitrogen gas (90—110K). 
The TEAS crystals belonged to the tetragonal space group 
P41212; the unit cell dimensions varied by a feW angstroms 
betWeen crystals, but on average a=126 A, c=122 The 
uncomplexed TEAS structure Was initially re?ned to 2.8 
A(Table 11) against data collected from a crystal groWn in 
the presence of 2 mM FHP (Table 10). Electron density at 
the active site alloWed unambiguous modeling of FHP, the 
A-C and J —K loops, and nine additional residues at the NH2 
terminus. The re?ned TEAS-FHP model consisted of resi 
dues 17 to 548, three Mg2+ions. 150 Water molecules, and 
one FHP molecule. The three-dimensional coordinates for 
TEAS in the presence of bound substrate is shoWn in Table 
10. The three-dimensional coordinates for TEAS in the 
absence of FHP is shoWn in Table 11. 
Crystals of TEAS complexed With tri?uoro-farnesyl 
diphosphate (F3-FPP) Were also prepared. In these crystals, 
a Well-ordered diphosphate binding pocket Was also 
observed. The A-C loop and the NH2-terminal segment 
exhibited Well-de?ned electron density, the A-C loop Was 
translated toWard the active site, and there Was strong 
electron density for the diphosphate moiety of F3-FPP. The 
hydrophobic pocket, hoWever, remained ?exible; the J-K 
loop and the farnesyl moiety of F3-FPP Were disordered. 
Homology models Were created and energy-minimiZed 
using the SWiss PDB vieWer interface of the SWissModel 
program (Peitsch M C (1996), Biochem. Soc. Trans., 
24:274—279 and Guex N. and Peitsch M C, 1997, 












































































































































































































